跳至主要内容
临床试验/2022-502814-99-00
2022-502814-99-00已完成1 期

A Phase 1, Open-label, Randomized, 2-Part, 2-Way Crossover Study in Healthy Adult Participants to Assess the Relative Bioavailability of Tablet Formulations of Lazertinib

Janssen - Cilag International, Janssen - Cilag International1 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2023年4月5日最近更新:

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
72
试验地点
1

研究概览

简要总结

暂无简介。

入排标准

年龄范围
18 years 至 64 years(18-64 Years)
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

发起方
Janssen - Cilag International, Janssen - Cilag International
申办方类型
Pharmaceutical company, Pharmaceutical company
责任方
Principal Investigator
主要研究者

CTIS Point of Contact

Scientific

Janssen - Cilag International

研究点 (1)

Loading locations...

相似试验

已完成
1 期
A Phase 1, open label, randomized, 2-sequence, 2-period, crossover, single center study to evaluate the pharmacokinetics of follitropin alfa from 2 manufacturing processes, administered as a single subcutaneous 450 IU dose to pituitary-suppressed healthy premenopausal female participants.Infertility
2023-507066-91-00Merck Healthcare KGaA14
招募中
1 期
A Phase I, Open-label, Randomized, Active-Controlled, to Evaluate the Safety and Immunogenicity of the DuoChol Oral Cholera Vaccine in 18 to 45 years old Healthy Participants in Sweden.
2025-522633-57-00International Vaccine Institute60
进行中(未招募)
1 期
A Phase 1, Open-label, Randomized, 2-Part, 2-Way Crossover Study in Healthy Adult Participants to Assess the Relative Bioavailability of Tablet Formulations of Lazertinib
CTIS2022-502814-99-00Janssen - Cilag International72
已完成
4 期
An open label, randomized, two-period, two-sequence, crossover bioavailability study to assess the pharmacokinetic and safety profile of Valacyclovir Oral Suspension compared to European sourced Valtrex® Tablets in normal, healthy subjects under fasting conditions.
2024-516184-87-00Dermax, Dermax30
招募中
1 期
A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients with Selected Advanced Cancers. Catherine Trial
2024-516660-28-01Vall D Hebron Institute Of Oncology15
A Phase 1, Open-label, Randomized, 2-Part, 2-Way... | 临床试验